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ABSTRACT
Hip or knee arthroplasty healthcare-associated infections (HAI) are a public health problem that
induces the increase of morbidity and mortality rates and poses an economic problem with
significant impact on hospitals budget. The infection rate in primary hip and knee
arthroplasties range between 1.5% and 2.5%, and is considered one of the main reasons for
surgeries non-effectiveness. A retrospective study was carried out in S. João Hospital Center,
EPE (CHSJ) to calculate HAI rate in primary hip and knee arthroplasties, and to analyse their
direct costs, for a better understanding of their economic impact. Four hundred and eighty
seven arthroplasties were studied and infection was noticed in 11 cases: 3 after hip and 8
after knee arthroplasties. Data collected from infected patients-related costs were compared
with the average cost of non-infected patients (standard). An incidence rate of 2.17% for hip
arthroplasties and 2.25% for knee arthroplasties was found. Results showed that patients
with infection remained in hospital 7.45 times longer than uninfected patients and incurred
hospital costs almost 3.8 times higher. This work shows how important is the quantification
of additional HAI costs to allow hospital managers to weigh the cost/benefit ratio and better
justify investments in HAI prevention and control programmes.
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Introduction
Healthcare-associated infections (HAI) became one of
the most common adverse events associated with
health systems, through an adverse impact on hospital
expenses and compromising healthcare quality and
effectiveness.
At international level, health systems have been
facing a continuous rise in expenditures, and Portugal
followed this trend, currently representing 26% of state
expenditure (2006 figures) and 10.6% of Gross Dom-
estic Product (GDP) [1].
The economic costs related with HAI can be noticed
through the increase at the average length of stay, usage
of antibiotics and other drugs, employment of more
diagnostic and therapeutic means and resources, in
addition to other social and intangible costs. These
excesses significantly increase hospital expenses,
which, in turn, have increasingly scarce resources.
Additionally, consuming resources on treating this
type of infections (again, potentially preventable) pro-
mote a decrease of available resources to allocate to
other areas of care. Therefore, the importance of accu-
rate economic assessment of HAI costs is evenmore sig-
nificant since quantifying the additional costs associated
with HAI, will support hospital managers in the
development of health policies dedicated to infection
prevention and control, thus reducing their impact [2].
The advances made in healthcare during the last
decades have led to a significant increase in the average
life expectancy, especially in industrialized countries
[3]. In accordance, the promotion of active aging is a
growing challenge for society and health systems to
ensure that elderly population lives in a healthy, auton-
omous and independent way as long as possible [4].
However, and despite all efforts, aging of population
is still associated with the prevalence of degenerative
diseases, such as those associated with hip and knee
joints [3,5].
As a result, hip and knee arthroplasties are cur-
rently the most common surgical procedures and,
when successful, significantly improving patient’s
quality of life. However, the large volume of arthro-
plasties performed have to be considered, as well as
the increasing risk of prosthetic joint infection
(between 1.5% and 2.5% of all knee and hip arthro-
plasties, tend to become infected) [6–11]. This is con-
sidered to be one of the most serious complications
that can occur after an arthroplasty.
This said, we are faced with an emerging issue and
hospital infection’s rate is currently assumed as one
of the indicators of clinical effectiveness and patient
safety [12,13].
Naturally, this problem is also of increasing impor-
tance in terms of healthcare management in Portugal,
but, despite its importance being widely recognized,
Portuguese studies about HAI costs are rare.
The main objectives of this study were: to identify
the infection rate in primary hip and knee arthroplas-
ties, to determine the intrinsic risk factors (comorbid-
ities) in the infected patients and, above all, to
analyse the direct costs related to surgical treatment,
by comparing the cost associated with infected patients
with the average cost of the non-infected patients
(standard), in order to better understand their econ-
omic impact in health systems.
Methodology
An observational, analytical and retrospective study was
carried out in a group of patients hospitalized in the
Orthopaedic Department from de S. João Hospital Cen-
ter, EPE (CHSJ), who underwent hip or knee arthroplas-
ties within a two years’ period, between May 2014 and
May 2016. In this case study, the average costs for unin-
fected primary arthroplasty from all patients (standard
cost) were compared with the average costs of infected
primary arthroplasty (infected patients).
Data were collected using the computer software
HSJ.IEG – Epidemiological and Management Infor-
mation. A list of all primary hip and knee arthroplasties
performed in the orthopaedic department during the
study period was consulted using ICD-9 procedure
codes: 81.51 for total hip replacement, 81.52 for partial
hip replacement and 81.54 for total knee replacement.
From this research, electronical clinical records (with
data encryption) off all patients who underwent hip or
knee arthroplasties during the study periodwere obtained.
Using the software SClínico, and with the support of
an orthopaedic specialist, all the electronical clinical
records of all these patients were analysed. Infected
patients were identified through records that showed
re-interventions and/or re-hospitalizations following
primary arthroplasty.
To obtain the direct costs of infected patients, the
variables presented in Table 1 were considered.
After data collection, a descriptive statistical analysis
was performed in order to understand the data distri-
bution and to compare the data obtained for infected
patients with standard data.
This study was approved by the ethical commission
of the S. João Hospital Center, EPE (CHSJ), and data
confidentiality and anonymity of participants were
ensured using a codification system.
Results
The study’s sample consisted of a total of 487 arthro-
plasties (138 hip arthroplasties and 349 knee arthro-
plasties), mainly constituted by female patients
(73.3%). The patients’ age ranged from 29 to 83
years, with a mean age of 67.8 years (67.9 for the hip
and 67.8 for the knee). Regarding the 487 surgical pro-
cedures performed, 11 infected arthroplasties were
detected: 3 of them occurred after primary hip arthro-
plasty and 8 after primary knee arthroplasty.
From these results, incidence rates of infection of
2.17% for hip arthroplasties and 2.25% for knee arthro-
plasties, were obtained. Both of these values are similar
to those reported in most international studies. Concern-
ing age, the patients that developed infections were
between 46 and 83 years old, and the age groups most
affected were the 60–69 and 80–89 groups. Intrinsic
risk factors like obesity, diabetes or hypertension, have
a big influence on the development of infection since
most of the patients are below optimal health status.
These factors, also called comorbidities, if not controlled,
may contribute to the onset of an infection. In this study,
despite diabetes being present in two infected patients,
Obesity was present in three of the infected patients
and hypertension in five. However, it was not possible
to establish the relation cause-effect between the presence
of comorbidities and the occurrence of infections.
Length of stay: infected patient vs. uninfected
patient
The length of stay is one of the most discrepant factors
when comparing the non-infected patients with the
infected patients. In the overall analysis of our sample,
the length of stay of infected patients was significantly
Table 1. Variables and costs considered to direct cost determination.
Variable Cost
Hospitalization daily costs (Average daily cost) 182.34 €
New Hip prosthesis costs (in the cases where there was replacement of the initial prosthesis) (kit’s price) 1320.80€
New Knee prosthesis costs (in the cases where there was replacement of the initial prosthesis) (kit’s price) 1000.00 €
Intervention costs (includes fixed staff costs, External Service Provision and depreciations) (Average cost) 654.98 €
Cost of revision materials (in cases where there was revision with replacement of a prosthesis component) *
Cost of materials for clinical consumption (with the exception of the prosthesis) used for to the patient during the re-hospitalization episode **
Medication costs; **
Complementary Diagnostic and Therapeutic Means (CDTMs) (Average daily cost per patient) 10.19 €
Orthopaedic follow-up cost due to infection (Average cost) 28.79 €
Notes: *Cost of revision materials – In case of a prosthesis review, the material used (e.g. revision stem, tibial and femoral revision component) was deter-
mined using specific values presented by the hospital analytical accounting. This value was based on acquisition costs of these materials for each patient.
**Regarding materials for clinical consumption and medication, it was possible to determine the specific costs for each patient.
higher than for those not infected. The uninfected
patient (standard patient) had 6.46 days as a mean
length of stay, while an infected patient remained in
the hospital 41.7 more days (mean). Therefore, the
length of stay was, on average, 7.45 times higher in
infected patients, which reveals values much higher
than those found in the literature review.
HAI direct costs:
In order to evaluate and quantify HAI associated costs, a
comparison between the average of the 487 primary
arthroplasty performed (which is referred as the standard
cost) and the average of infected patients’ costs wasmade.
Based on all the variables thatwere analysed, the standard
cost of a patient undergoing primary arthroplasty of the
hip or knee was calculated first (Table 2).
From the sum of the first six items of Table 1, the cost
of hospitalization without complications was obtained
(Column 7). However, patients who underwent primary
arthroplasty had, on average, 5.8 follow-up visits. For
infected patients, data is shown in Table 3.
Since all the infected patients had the first hospital-
ization without complications and a subsequent hospi-
talization due to the appearance of the infection, it was
decided to show the costs of the first hospitalization, to
compare them with those obtained for the standard
patient, and then add to the value obtained the
additional costs associated with the development of
the infection: costs of re-hospitalization and follow-
up visits. In this way, the total cost for each of the
infected patients was obtained (Table 2).
Considering the patient H specificity, the mean cost
per infected patient resulted from the addition of the
total costs of the infected patients, but instead of divid-
ing by 10 (n° re-hospitalizations) was divided by 11
(number of arthroplasties infected).
According to the results obtained for the cost of an
infected patient’s treatment, on average, it was 3.8
times higher than a standard patient’s treatment.
Taking into account that the standard mean cost for
uncomplicated primary arthroplasty was 3411.78€ and
patients who acquired an infection had a total of 11
hospitalizations in which they underwent primary
arthroplasty, the hospital would be expected to spend
approximately 37,529.58 €, if no infection had been
acquired. However, the hospital spent on the 10 read-
missions that corresponded to 11 infected arthroplas-
ties, a total of 143,249.19 €, which represents a
surplus cost of 105,719.61 €.
Based on the extra costs, the opportunity cost of per-
forming primary arthroplasty was also calculated. That
is, if no infection had been acquired and the primary
arthroplasty had occurred without complications,
approximately 31 more primary hip or knee arthro-
plasties could have been performed in this period.
Discussion
As shown in this study the incidence rates of infection
are similar to those reported in most international
studies. According to Taylor et al. [10], between 1.5%
and 2.5% of all knee and hip arthroplasties tend to
become infected. Related to common comorbidities,
and according to a European study conducted by Tum-
barello et al. [14], the most common comorbidities
among patients with HAI were diabetes (27.8%), neo-
plasms (27.8%) and malignant haematological disease
(22.2%). In this study, despite diabetes being present
in two infected patients, two others comorbidities
stood out from all others, due to their incidence on
the infected patients: obesity and hypertension.
The length of stay is one of the most discrepant fac-
tor comparing with literature. According to Plowman
[15], the infected patients showed the length of stay
2.5 times higher when compared to patients who did
not develop any infection. However, in this study, it
was, on average, 7.45 times higher in infected patients,
which reveals values much higher than those found in
the literature review. This value may be due to the rela-
tively small number of infected patients present in the
sample, and to the fact that some of them have shown
Table 2. Average cost of patients who underwent primary arthroplasty (standard cost).
Hospitalization
costs (€)
Prosthesis
cost (€)
Intervention
costs (€)
Medication
(€)
Material for
clinical
consumption (€)
Average cost
for CDTMs
per patient
(€)
Total
hospitalization cost
without
complications (€)
Costs of
orthopeadic
follow-up visits
(€)
Total direct
cost per
patient (€)
1177.16 1090.90 654.98 45.99 209.98 65.79 3244.80 166.98 3411.78
Table 3. Costs comparison between infected and uninfected
patients.
Patient
Infected
Prosthesis
Primary
arthroplasty
costs (€)
Additional
infection
costs (€)
Total cost per
infected
patient (€)
A Knee 2985.66 2783.07 5768.73
B Knee 2144.00 11,778.03 13,922.03
C Hip 4824.68 9127.53 13,952.21
D Hip 3130.05 33,058.42 36,188.47
E Knee 3029.12 3637.70 6666.82
F Hip 4215.63 4758.44 8974.07
G Knee 2896.64 9495.19 12,391.83
H Knee 6645.49a 17,185.93 23,831.42*
I Knee 3137.99 12,577.58 15,715.57
Knee 3.095 2743.04 5838.04
Average cost per infected patient (€): 13,022.65
aPatient H had two hospitalizations in which he underwent arthroplasty of
the right knee and left knee respectively. He was re-hospitalized due to
an infection of the right knee prosthesis and during the hospitalization he
also acquired an infection on the left knee prosthesis. Therefore, it was
agreed to add the costs of the two initial hospitalizations and sum it to
the additional cost caused by the re-hospitalization, where he acquired
the infection in both prostheses. Therefore, the 23.831.42 € correspond
to the total cost of two infected arthroplasties.
extremely high length of stay. It is also important to
highlight the burden of the length of stay on the cost
of the infected patients. Some studies reported the
length of stay as the factor with the highest cost for
an infected patient [11,16–18] and in this study, this
is also verified. We found that, on average, 61.74% of
the costs of the infected patients were due to the
costs of re-hospitalization stay.
Regarding the direct costs with SSI, it is worth men-
tioning that, compared to other studies, costs were
slightly higher. However, the cost analysis carried out
by this study was a comprehensively more detailed
than most of the literature consulted on this subject,
which is considered to be an advantage. Differently
from the majority of the published studies, not only
the costs of hospitalization and re-hospitalization of
the infected patients were considered but also the
costs of subsequent orthopaedic consultations were
included. In this way, the total direct cost of the patient
with SSI was obtained, which is considered to be a
more complete analysis of the SSI costs related to hip
and knee arthroplasties.
Limitations
Throughout the study, some difficulties occurred,
namely in the calculation of the direct costs to the hos-
pital due to SSI. This means that it was not always poss-
ible to obtain the direct costs, so certain items were
calculated with the average values of the CHSJ records.
The temporal limitation of data collection is another
relevant issue. As stated before, all patients undergoing
primary hip or knee arthroplasty between May 2014
and May 2016 were considered, and it is noticed that
a 12-month follow-up of the patient after surgery is
usually performed. However, by the end of this
research, many patients had not yet been followed up
therefore, some infections may occur on these patients
beyond the period considered in this study.
Conclusions
In this study, it was possible to identify and quantify
hip and knee arthroplasties infection rates and their
direct cost. The results, obtained by comparing the
costs of the length of stay, surgical interventions, anti-
biotics used, materials of clinical consumption and
complementary diagnostic and therapeutic means in
the infected and non-infected patients, are in accord-
ance with the literature review.
In Portugal, there are few studies about HAI costs
and, as mentioned previously, this research was
intended to be a contribution in an area where studies
are scarce and at the same time contribute to demystify
the idea that health care related costs are not feasible to
evaluate. The results of this study are also very impor-
tant to increase awareness about HAI costs, supported
by an accurate economic assessment. In addition,
quantifying costs associated with HAI, will allow hospi-
tal managers from S. João Hospital Center to weigh the
cost/benefit ratio and better justify investments in HAI
prevention, especially since it is known that a large
number of Infections could be prevented.
New studies to determine the HAI costs using larger
samples and longer follow-up times should be devel-
oped, so that it may be possible to achieve a more rig-
orous evaluation of the economic impact of HAI in
health systems. This knowledge will contribute to bet-
ter know the HAI economic problem to support the
decision-making process, and help healthcare man-
agers all over the world to better decide about new
investments in HAI prevention and control pro-
grammes based on supported cost-benefits analysis.
[4] DGS. Programa Nacional para a Saúde de Pessoas
Idosas. Direção Geral de Saúde; 2004.
[5] Schairer WW, Sing DC, Vail TP, et al. Causes and fre-
quency of unplanned hospital readmission after total
hip arthroplasty. Clin Orthopaed Related Res.
2014;472:464–470.
[6] Fonseca F. Infecção em artroplastias do joelho. Revista
Portuguesa de Ortopedia e Traumatologia. 2006:
109–125.
[7] Bertucci FN, Tedrus GMAS. Infecções em próteses
ortopédicas: revisão da literatura. Anais do XV
Encontro de Iniciação Científica da PUC-Campinas
Campinas; 2010.
[8] Freitas F, Virgolino M, Ribeiro C. Infecção de prótese
articular da anca e joelho. Revista Portuguesa de
Ortopedia e Traumatologia. 2013: 165–172.
[9] Garrido-Gómez J, Arrabal-Polo MA, Girón-Prieto MS,
et al. Descriptive analysis of the economic costs of peri-
prosthetic joint infection of the knee for the public
health system of Andalusia. J Arthroplasty.
2013;28:1057–1060.
[10] Taylor EN, Webster TJ. The use of superparamagnetic
nanoparticles for prosthetic biofilm prevention. Int J
Nanomed. 2009;4:145–152.
[11] Moura J, Baylina P, Moreira P. Exploring the real costs
of healthcare-associated infections: an international
review. Int J Healthcare Manage. 2017: 1–8. doi:10.
1080/20479700.2017.1330729.
[12] Veillard J, Guisset A-L, Garcia-Barbero M. Selection of
indicators for hospital performance measurement. A
Report on the 3rd and 4th WHO Workshop
Barcelona, Spain, June and September: 2003.
[13] WHO.Measuring hospital performance to improve the
quality of care in Europe: a need for clarifying the con-
cepts and defining the main dimension. Report on a
WHO Workshop Barcelona, Spain. 2003: 10–11.
[14] Tumbarello M, Repetto E, Trecarichi E, et al.
Multidrug-resistant Pseudomonas aeruginosa blood-
stream infections: risk factors and mortality.
Epidemiol Infect. 2011;139:1740–1749.
[15] Plowman R. The socioeconomic burden of hospital
acquired infection. Euro Surveill. 2000;5:49–50.
[16] Bôas P, Ruiz T. Ocorrência de infecção hospitalar em
idosos internados em hospital universitário. Rev
Saúde Pública. 2004;38:372–378.
[17] Kirkland KB, Briggs JP, Trivette SL, et al. The impact
of surgical-site infections in the 1990s: attributable
mortality, excess length of hospitalization, and
extra costs. Infect Control Hosp Epidemiol.
1999;20:725–730.
[18] Rocha LÁ. Vigilancia de la infección nosocomial en la
UCI. Medicina Intensiva. 2002;26:61–63.
References
[1] Borges CM, Ramalho R, Bajanca M, et al.
Implementação de um sistema de custeio por activi-
dades nos hospitais do SNS. Revista Portuguesa de
Saúde Pública. 2010;9:141–160.
[2] Fukuda H, Lee J, Imanaka Y. Variations in analytical
methodology for estimating costs of hospital-acquired
infections: a systematic review. J Hospital Infect.
2011;77:93–105.
[3] Widmer AF. New developments in diagnosis and treat-
ment of infection in orthopedic implants. Clin Infect
Dis. 2001;33:S94–S106.
